Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza

References

• Sedyaningsih ER, Isfandari S, Setiawaty V et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005–June 2006. J. Infect. Dis.196(4), 522–527 (2007).
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit. Care Med. DOI: 10.1097/CCM.0b013e3181c92eeb (2009) (Epub ahead of print).
   Google Scholar
• Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA302(17), 1872–1879 (2009).
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med.361(7), 680–689 (2009).
   PubMed Web of Science ®Google Scholar
• de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med.12(10), 1203–1207 (2006).
   PubMed Web of Science ®Google Scholar
• Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis.198(7), 962–970 (2008).
   PubMed Web of Science ®Google Scholar
• Davies A, Jones D, Bailey M et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA302(17), 1888–1895 (2009).
   PubMed Web of Science ®Google Scholar
• Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine26(Suppl. 4), D5–D9 (2008).
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Kockler DR. Trivalent intranasal influenza vaccine, live. Ann. Pharmacother.38(12), 2086–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect Dis. J.23(2), 138–144 (2004).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol.176(10), 6333–6339 (2006).
   PubMed Web of Science ®Google Scholar
• Bleshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356, 685–696 (2007).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics116(3), e397–e407 (2005).
   PubMed Web of Science ®Google Scholar
• Schechter R, Grether JK. Continuing increase in autism reported to Californias’s developmental services system: mercury in retrograde. Arch. Gen. Psychiatry65(1), 19–24 (2008).
   PubMed Web of Science ®Google Scholar
• McMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosol-free or thimerosol-containing vaccine. Vaccine26(3), 427–429 (2008).
   PubMed Web of Science ®Google Scholar
• Oxford JS. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respi. Viruses1(1), 27–34 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit. Care Med. DOI: 10.1097/CCM.0b013e3181c85229 (2009) (Epub ahead of print).
   Google Scholar
• De Clercq E. Antiviral agents active against influenza viruses. Nat. Rev. Drug Discov.5(12), 1015–1025 (2006).
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X et al. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet366(9492), 1175–1181 (2005).
   PubMed Web of Science ®Google Scholar
• He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res.77(1), 72–76 (2008).
   PubMed Web of Science ®Google Scholar
• de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med.353(25), 2667–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Boltz DA, Douangngeun B, Phommachanh P et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao PDR. J. Gen. Virol. DOI: 10.1099/vir.0.017459-0 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother.53(10), 4433–4440 (2009).
   PubMed Web of Science ®Google Scholar
• Steain MC, Dwyer DE, Hurt AC et al. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. Antiviral Res.83(3), 242–248 (2009).
   Google Scholar
• Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis.48(9), 1254–1256 (2009).
   PubMed Web of Science ®Google Scholar
• Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA301(10), 1034–1041 (2009).
   PubMed Web of Science ®Google Scholar
• Scalera NM, Mossad SB. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad. Med.121(5), 43–47 (2009).
   PubMed Web of Science ®Google Scholar
• La Force C, Man CY, Henderson FW et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.29(8), 1579–1590, discussion 1577–1578 (2007).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J. Infect.56(1), 51–57 (2008).
   PubMed Web of Science ®Google Scholar
• Kidd IM, Down J, Nastouli E et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet374(9694), 1036 (2009).
   PubMed Web of Science ®Google Scholar
• Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol.83(20), 10366–10373 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Wilson SZ, Knight V et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother.27(3), 309–313 (1985).
   PubMed Web of Science ®Google Scholar
• Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N. Engl. J. Med.361(17), 1713–1714 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert BE, McLeay MT. Megaribavirin aerosol for the treatment of influenza A virus infections in mice. Antivir. Res.78(3), 223–229 (2008).
   PubMed Web of Science ®Google Scholar
• Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine25(16), 3175–3178 (2007).
   PubMed Web of Science ®Google Scholar
• Wong JP, Christopher ME, Viswanathan S et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr. Pharm. Des.15(11), 1269–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Wong JP, Christopher ME, Viswanathan S et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine27(25–26), 3481–3483 (2009).
   PubMed Web of Science ®Google Scholar
• Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One4(1), e4176 (2009).
   PubMed Web of Science ®Google Scholar
• Sindoni D, La Fauci V, Squeri R et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J. Prev. Med. Hyg.50(2), 121–126 (2009).
   PubMedGoogle Scholar
• Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med.361(25), 2414–2423 (2009).
   PubMed Web of Science ®Google Scholar
• Quispe-Laime AM, Bracco JD, Barberio PA et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med.36(1), 33–41 (2009).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir. Viruses3(4), 129–142 (2009).
   PubMed Web of Science ®Google Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines8(12), 1681–1692 (2009).
   PubMed Web of Science ®Google Scholar